Olumiant Could Boost Incyte’s Revenues
In February 2017, Eli Lilly (LLY) secured approval for Olumiant (baricitinib) from the European Medicines Agency (or EMA) for patients suffering from moderate-to-severe rheumatoid arthritis.
Healthcare
The latest news in the healthcare sector including biotech and telehealth.
Eylea Could Continue to Generate High Revenue
Regeneron Pharmaceuticals (REGN) markets Eylea in the United States, and Bayer (BAYZF) commercializes the drug outside the US market.
The Latest on TEVA’s Oncology Business
In 1H17, Teva Pharmaceutical’s (TEVA) oncology business generated revenues of ~$550 million, or ~9% lower YoY (year-over-year).
Understanding the Performance of Merck’s Hospital Acute Care Drugs Noxafil and Cubicin
In 4Q17, Merck’s (MRK) Cubicin reported revenues of $92 million, which was ~23% lower on a YoY (year-over-year) basis.
Pfizer Reports 1Q18 Earnings and Revenue Growth
Pfizer (PFE) released its 1Q18 earnings today, reporting another strong quarter for the Innovative health business.
BIIB Stock Tumbles as Alzheimer Drug BAN2401 Data Failed to Impress Investors
Today, Biogen (BIIB) and partner Eisai presented highly anticipated detailed study data for their investigational Alzheimer’s drug BAN2401.
Can Edwards Lifesciences See Robust Net Profit Margin in 2017?
In its 2Q17 earnings conference call, Edwards Lifesciences (EW) projected 2017 adjusted EPS to fall to $3.65–$3.85, which is higher than the previous $3.43–$3.55.
Teva Announces First-to-File Launch of Generic Cialis
Yesterday, Teva Pharmaceutical Industries (TEVA) announced the exclusive FTF (first-to-file) launch of the generic Cialis1 tablets in the US.
How’s Celgene’s Abraxane Positioned after 4Q17?
In 4Q17, Celgene’s (CELG) Abraxane generated revenues of $251 million, which reflected a decline of ~6% on a YoY (year-over-year) basis.
Why the US Moat Index Beat the S&P 500 Index in July
Domestic moat companies, as represented by the Morningstar® Wide Moat Focus IndexSM (MWMFTR, or “U.S. Moat Index”), once again posted strong results in July.
Who Owns Pfizer?
On Nov. 9, Pfizer announced that its coronavirus vaccine is more than 90 percent effective. Who owns Pfizer and where is the company based?
Will Amazon Disrupt the Pharmacy Industry?
In Amazon's latest push into healthcare, the company has launched Amazon Pharmacy. Will Amazon disrupt the pharmacy industry?
Will McKesson Stock Benefit from COVID-19 Vaccine?
McKesson stock has soared as the pandemic has created a business boom for the company. Will vaccines reverse the gains?
Who Owns Pfizer and BioNTech?
The Pfizer-BioNTech vaccine holds life-changing potential. Who are the owners that are running the show?
Who Owns Moderna?
Moderna, a biopharmaceutical company, has a coronavirus vaccine with initial trial results that show 94.5 percent effectiveness.
Should You Buy Peloton Stock After the Recent Fall?
Peloton stock has been under pressure amid positive news about COVID-19 vaccine candidates. Should you buy PTON stock after the recent crash?
Is AstraZeneca Stock a Good Buy at These Prices?
AstraZeneca was founded in 1999 through the merger of Astra AB and Zeneca Group. Is AstraZeneca a good stock to buy?
Cigna’s Stock Split History: Is Another Split Due in 2020?
Stock splits have made headlines this year. When will Cigna stock split, and would a split make any difference to investors?
UnitedHealth Posts Outstanding Q3 Results, Beats Expectations
Today, UnitedHealth announced its third-quarter 2020 earnings results. The company has scheduled an earnings conference call at 8:45 a.m. ET today.
What Are the Top Cannabis Penny Stocks in 2020?
Cannabis stocks have been in a freefall over the last two years. What are the top marijuana penny stocks in 2020?
Can College Students Qualify for Medicaid Benefits?
College students may qualify for Medicaid depending on the state they live in and their family income level.
TalkSpace Teletherapy App Prepares to Go Public In Next Six Months
TalkSpace Teletherapy App Prepares to Go Public in Next Six Months With $1 Billion Valuation
What Are the Best Affordable Health Insurance Companies?
Finding affordable health insurance can be a difficult prospect, especially if you or your loved ones have an underlying health condition. However, there are affordable options out there.
Why Plasma Stocks Are on Investors’ Radar
Plasma stocks popped up after the FDA cleared hospitals to use plasma-derived therapy to treat COVID-19 patients.
Pfizer CEO Says COVID-19 Vaccine Could be Ready This Year
Albert Bourla, CEO of pharmaceutical giant Pfizer, has said there is a 60 percent chance that the company's scientists will know whether their vaccine is effective by the end of October.
Operation Warp Speed Has Invested Billions in Potential COVID-19 Vaccines
The U.S. government’s Operation Warp Speed program has already invested billions in six potential coronavirus vaccine candidates.
The Supreme Court Will Rule on Obamacare This Fall, but Congress May Have Already Saved It
Is Obamacare still in effect? The Affordable Care Act is still law, but its constitutionality depends on an upcoming Supreme Court decision.
Aetna, BCBS, and Cigna Are Among the Top Health Insurance Companies
Selecting a health insurance company can be a daunting task. What are the topi health insurance companies that individuals should consider?
Moderna Stock Soars, COVID-19 Vaccine Looks Promising
Moderna (NASDAQ:MRNA) stock surged 16% in after-market trading hours on Tuesday following news of positive results related to its COVID-19 vaccine.
Moderna Partners with Catalent on Potential COVID-19 Vaccine
Today, biotechnology company Moderna announced its collaboration with Catalent for large-scale manufacturing of its potential COVID-19 vaccine.
Amarin Stock Drops After Vascepa Appeal Hearing
Amarin stock dropped 31 percent yesterday in response to the company’s Vascepa appeal hearing.Must-know: Concur is the biggest acquisition in SAP’s history
Since 2010, SAP AG (SAP) spent more than ~$12 billion on acquisitions. Concur Technologies is the largest acquisition in SAP’s 42-year history. In its 2Q14 results, most of SAP’s growth was from its cloud business—approximately $1 billion annually. Concur’s management mentioned that they expect to end fiscal year 2014 with ~$690 million.
U.S. Approves Coronavirus Treatment, FTSE 100 Jumps on Possible AstraZeneca Vaccine Approval
Monday could prove to be a good day for the markets after positive news about coronavirus treatments and vaccines.
Regeneron to Partner With Roche on COVID-19 Drug
Roche Holding has agreed to help develop and distribute an experimental COVID-19 drug in partnership with Regeneron Pharmaceuticals.
A Financial Overview of Bausch Health in October
Bausch Health’s (BHC) net revenues declined from $4.3 billion in H1 2017 to $4.1 billion in H1 2018, reflecting an ~5.0% year-over-year decline.
Chilton opens a new position in Abbott Laboratories in 4Q13
Abbott Laboratories (ABT) is a brand new position that accounts for 1.19% of Chilton’s fourth quarter 2013 portfolio.
Myriad Genetics Expected to Report Flat Revenue Growth in Fiscal 2018
Myriad Genetics (MYGN) expects to report revenues in the range of $750 million–$770 million in fiscal 2018 (ended June 30, 2018).
A Look at Spectrum’s Financial Position in September
In the second quarter, Spectrum Pharmaceuticals (SPPI) generated net revenues of $24.2 million compared to $34.3 million in Q2 2017.
U.S. States With Legal Recreational Marijuana Use in 2020
Recreational marijuana laws vary between states. Elections are around the corner, and more states have recreational use laws on the 2020 ballot.
An Easier Way to Understand the Pharma Industry
In 2018, the global pharmaceutical industry stood at $1.2 trillion, and experts expect $1.5 trillion by 2023. Here’s everything investors need to know.
Will Walgreens’ Q3 Results Beat Wall Street’s Forecast?
Unlike several other US companies, Walgreens didn’t suspend its dividends due to COVID-19. As of July 6, the company’s dividend yield was 4.2%.
Is Aphria a Viable Investment in the Cannabis Space?
Cannabis stocks have underperformed the broader markets. Despite the underperformance, Aphria’s recent financial performance was impressive.
Bill Gross: Top Stock Picks with High Dividend Yields
On October 18, CNBC reported Bill Gross top picks. His top stock picks were Annaly Capital (NLY), Invesco (IVZ) and Allergan (AGN).Healthcare Analyzing hospital expenses: Breaking down the important costs
You can break down average hospital costs into salary expenses, supply expenses, bad debt expenses, and miscellaneous expenses. Labor costs account for about 49% of expenses, and they’re the biggest expenses for hospitals.
CVS Health Stock: What’s Fueling Growth and Will the Uptrend Last?
CVS Health stock is up about 13% in November. Strong financial performance is driving the stock higher, but low earnings growth could limit further upside.
Why you should use the Sharpe ratio when investing in the medical device industry
What is a Sharpe ratio? A Sharpe ratio is a tool that measures the amount of returns for each unit of volatility that’s generated by a portfolio (higher returns and lower volatility equals more returns per unit of volatility). The measurement allows investors to analyze how much return they’re receiving from a portfolio in exchange for […]Healthcare Overview: Assessing hospital companies’ capital expenditures
Capital projects in the hospital sector include purchasing new facilities, purchasing medical equipment, renovating and replacing existing hospitals, and investing in information systems infrastructure.Healthcare Understanding hospitals’ size, technology, and operating expenses
In the capital-intensive hospital industry, economies of scale offer a competitive advantage by spreading out the high fixed costs, providing for higher margins.
Point72 Asset Management takes position in CymaBay Therapeutics
CymaBay Therapeutics is a clinical-stage biopharmaceutical company formerly known as Metabolex. It develops therapies to treat metabolic and rare diseases with high unmet need.
Carl Icahn’s View on Share Buybacks Is Divided
Apple (AAPL) is one of the most cash-rich companies in the US. While Carl Icahn has been talking about share buybacks artificially inflating the Market and asset values, some buybacks have occurred as a result of his push.
